190 related articles for article (PubMed ID: 24920503)
1. [Personalized molecular medicine: new paradigms in the treatment of cochlear implant and cancer patients].
Zenner HP; Pfister M; Friese N; Zrenner E; Röcken M
HNO; 2014 Jul; 62(7):520-4. PubMed ID: 24920503
[TBL] [Abstract][Full Text] [Related]
2. [Pathophysiology of hearing loss : Classification and treatment options].
Kral A
HNO; 2017 Apr; 65(4):290-297. PubMed ID: 27299892
[TBL] [Abstract][Full Text] [Related]
3. Nucleic acid targeting: towards personalized therapy for head and neck cancer.
Parsel SM; Grandis JR; Thomas SM
Oncogene; 2016 Jun; 35(25):3217-26. PubMed ID: 26592450
[TBL] [Abstract][Full Text] [Related]
4. Cochlear implantation in common forms of genetic deafness.
Vivero RJ; Fan K; Angeli S; Balkany TJ; Liu XZ
Int J Pediatr Otorhinolaryngol; 2010 Oct; 74(10):1107-12. PubMed ID: 20655117
[TBL] [Abstract][Full Text] [Related]
5. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
Yokota T
Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
[TBL] [Abstract][Full Text] [Related]
6. Towards a personalized treatment of head and neck cancer.
Gross AM; Cohen EE
Am Soc Clin Oncol Educ Book; 2015; ():28-32. PubMed ID: 25993138
[No Abstract] [Full Text] [Related]
7. [Personalized therapy concepts for malignant melanoma].
Schlaak M; Kreuzberg N; Mauch C; Kurschat P
Internist (Berl); 2013 Feb; 54(2):188-93. PubMed ID: 23371260
[TBL] [Abstract][Full Text] [Related]
8. [Breast cancer. Individualized therapy concepts].
Harbeck N; Wuerstlein R
Internist (Berl); 2013 Feb; 54(2):194-9. PubMed ID: 23371261
[TBL] [Abstract][Full Text] [Related]
9. Precision Therapy of Head and Neck Squamous Cell Carcinoma.
Polverini PJ; D'Silva NJ; Lei YL
J Dent Res; 2018 Jun; 97(6):614-621. PubMed ID: 29649374
[TBL] [Abstract][Full Text] [Related]
10. Molecular Imaging and Precision Medicine in Head and Neck Cancer.
Mena E; Thippsandra S; Yanamadala A; Redy S; Pattanayak P; Subramaniam RM
PET Clin; 2017 Jan; 12(1):7-25. PubMed ID: 27863568
[TBL] [Abstract][Full Text] [Related]
11. [Which platform to support a personalized lung cancer treatment?].
Ruppert AM; Antoine M; Beau-Faller M; Cadranel J; Wislez M
Bull Cancer; 2012 May; 99(5):529-34. PubMed ID: 22525302
[TBL] [Abstract][Full Text] [Related]
12. Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma.
Gong W; Xiao Y; Wei Z; Yuan Y; Qiu M; Sun C; Zeng X; Liang X; Feng M; Chen Q
Oncotarget; 2017 Jan; 8(2):2141-2152. PubMed ID: 27924064
[TBL] [Abstract][Full Text] [Related]
13. GJB2 gene mutations in cochlear implant recipients: prevalence and impact on outcome.
Lustig LR; Lin D; Venick H; Larky J; Yeagle J; Chinnici J; Polite C; Mhatre AN; Niparko JK; Lalwani AK
Arch Otolaryngol Head Neck Surg; 2004 May; 130(5):541-6. PubMed ID: 15148174
[TBL] [Abstract][Full Text] [Related]
14. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
15. Prediction of cochlear implant performance by genetic mutation: the spiral ganglion hypothesis.
Eppsteiner RW; Shearer AE; Hildebrand MS; Deluca AP; Ji H; Dunn CC; Black-Ziegelbein EA; Casavant TL; Braun TA; Scheetz TE; Scherer SE; Hansen MR; Gantz BJ; Smith RJ
Hear Res; 2012 Oct; 292(1-2):51-8. PubMed ID: 22975204
[TBL] [Abstract][Full Text] [Related]
16. [Personalized medicine in otology. The role of genetic diagnostics in patients with hearing impairment].
Friese N; Braun K; Müller M; Tropitzsch A
HNO; 2015 Jun; 63(6):428-33. PubMed ID: 26059788
[TBL] [Abstract][Full Text] [Related]
17. Potential application of tumor suppressor microRNAs for targeted therapy in head and neck cancer: A mini-review.
Olatunji I
Oral Oncol; 2018 Dec; 87():165-169. PubMed ID: 30527233
[TBL] [Abstract][Full Text] [Related]
18. Applications of molecular diagnostics for personalized treatment of head and neck cancer: state of the art.
Mes SW; Leemans CR; Brakenhoff RH
Expert Rev Mol Diagn; 2016; 16(2):205-21. PubMed ID: 26620464
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine in head and neck cancer.
Kaidar-Person O; Gil Z; Billan S
Drug Resist Updat; 2018 Sep; 40():13-16. PubMed ID: 30466712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
